GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qingdao Vland Biotech Co Ltd (SHSE:603739) » Definitions » EBIT

Qingdao Vland Biotech Co (SHSE:603739) EBIT : ¥149 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Qingdao Vland Biotech Co EBIT?

Qingdao Vland Biotech Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥28 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥149 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Qingdao Vland Biotech Co's annualized ROC % for the quarter that ended in Mar. 2024 was 2.84%. Qingdao Vland Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 6.82%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Qingdao Vland Biotech Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 4.04%.


Qingdao Vland Biotech Co EBIT Historical Data

The historical data trend for Qingdao Vland Biotech Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qingdao Vland Biotech Co EBIT Chart

Qingdao Vland Biotech Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 99.49 141.93 173.53 109.36 137.71

Qingdao Vland Biotech Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.23 32.90 40.02 47.56 28.07

Competitive Comparison of Qingdao Vland Biotech Co's EBIT

For the Biotechnology subindustry, Qingdao Vland Biotech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qingdao Vland Biotech Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Qingdao Vland Biotech Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Qingdao Vland Biotech Co's EV-to-EBIT falls into.



Qingdao Vland Biotech Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥149 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qingdao Vland Biotech Co  (SHSE:603739) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Qingdao Vland Biotech Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=97.4 * ( 1 - 24.24% )/( (2586.892 + 2610.666)/ 2 )
=73.79024/2598.779
=2.84 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3034.058 - 411.399 - ( 531.642 - max(0, 1088.174 - 1123.941+531.642))
=2586.892

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3026.159 - 374.711 - ( 508.824 - max(0, 1068.439 - 1109.221+508.824))
=2610.666

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Qingdao Vland Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=112.26/( ( (1505.277 + max(132.626, 0)) + (1490.767 + max(165.174, 0)) )/ 2 )
=112.26/( ( 1637.903 + 1655.941 )/ 2 )
=112.26/1646.922
=6.82 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(322.737 + 205.405 + 30.802) - (411.399 + 0 + 14.919)
=132.626

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(319.44 + 213.162 + 27.509) - (374.711 + 0 + 20.226)
=165.174

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Qingdao Vland Biotech Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=148.547/3675.521
=4.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qingdao Vland Biotech Co EBIT Related Terms

Thank you for viewing the detailed overview of Qingdao Vland Biotech Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Qingdao Vland Biotech Co (SHSE:603739) Business Description

Traded in Other Exchanges
N/A
Address
No. 1318, Wangsha Road, Room 108, Enterprise Service Center, Chengyang District, Shandong, Qingdao, CHN, 266061
Qingdao Vland Biotech Co Ltd is a biotechnology company. The company is engaged in research and development of four main product categories which are enzymes, probiotics, vaccines and animal health products.
Executives
Chen Gang Director
Jia De Qiang Director
Cao Cheng Director
Jiang Yong senior management
Xu Yong Supervisors

Qingdao Vland Biotech Co (SHSE:603739) Headlines

No Headlines